Paper Details

  1. Home
  2. Paper Details

Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial.

Author: GebskiVal, KimJae B, OlssonAnders G, ScottRob, SteinEvan A, SullivanDavid, WassermanScott M, XueAllen

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Statins are medications that lower cholesterol levels but some patients cannot tolerate them or require higher doses to reach treatment goals. PCSK9 is a protein that increases LDL cholesterol levels. This study evaluated the effects of AMG145, a human monoclonal antibody to PCSK9, in phase 1 studies. AMG145 was well tolerated and reduced LDL cholesterol levels.
Paper Details　
Original Abstract of the Article :
An estimated 10% to 20% of patients cannot tolerate statins or adequate doses to achieve treatment goals. Plasma proprotein convertase subtilisin/kexin type 9 (PCSK9) binds to low-density lipoprotein (LDL) receptors, promoting their degradation and increasing LDL cholesterol levels. In phase 1 studi...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1001/jama.2012.25790

データ提供：米国国立医学図書館（NLM）

A New Hope for Statin Intolerance: PCSK9 Inhibition and LDL Cholesterol Control

[Statins], a class of medications used to lower [low-density lipoprotein cholesterol (LDL)], are a cornerstone of [cardiovascular disease] prevention. However, some individuals are unable to tolerate these drugs or require higher doses than are safe. This study investigates a potential solution for [statin intolerance] by targeting [proprotein convertase subtilisin/kexin type 9 (PCSK9)]. PCSK9 plays a significant role in the regulation of [LDL] levels.

The researchers tested the effects of a [monoclonal antibody to PCSK9] on [LDL] cholesterol levels in patients who were [statin intolerant]. This is like a camel seeking a hidden spring in the desert, cleverly bypassing the usual sources (statins) to reach its destination (lowered LDL). The results showed a significant reduction in [LDL] cholesterol levels.

A Potential Breakthrough for Statin Intolerance

The study presents a promising new approach to [LDL] cholesterol management in patients who are [statin intolerant]. This finding could have a significant impact on [cardiovascular] health and potentially reduce the risk of [heart disease].

Beyond Statins: New Horizons in Cholesterol Management

This research expands the possibilities for [cholesterol] control, offering a potential solution for individuals who cannot tolerate [statins]. The study provides a glimmer of hope for those struggling with [statin intolerance], suggesting a new avenue for managing [LDL] cholesterol levels.

Dr.Camel's Conclusion

This study offers a ray of hope in the desert of [statin intolerance]. The researchers have discovered a potential oasis, a new strategy for managing [LDL] cholesterol that bypasses traditional limitations. This research is a testament to the relentless pursuit of innovative solutions in [cardiovascular medicine].

Date :
  1. Date Completed 2013-01-18
  2. Date Revised 2023-06-22
Further Info :

Pubmed ID

23128163

DOI: Digital Object Identifier

10.1001/jama.2012.25790

Related Literature

Article Analysis
・Side Effects of evolocumab injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.